Skip to main content

Nurix Therapeutics, Inc Investor Event Transcript, Nov 18, 2026

Nurix Therapeutics, Inc. (NRIX)

Sanofi has terminated the STAT6 phase one program, which it told Nurix about a couple of weeks ago, but the partnership and other STAT6 programs remain in place. Nurix has not yet received any data from Sanofi and has requested full reports. AI summary

Investor Event Transcript 2026-11-18 For: 2026-11-30
Added on November 18, 2026

Conference Transcript - NRIX 2026-11-18

Roger Song, Analyst — Jefferies

Okay. All right. Welcome, everyone, to the 2026 Jeffrey's Global Healthcare Conference. My name is Roger Song, senior, and this covers Micah Biotech in the U.S. It is my pleasure to have the fireside chat with Nurex Therapeutics. We have a CEO as a sender.

Arthur T. Sands, CEO

All right. Thank you, Roger. Thanks for having us.

Roger Song, Analyst — Jefferies

Awesome. All right, Arthur, before we dive into the specifics, maybe you can give us a one or two minutes overview of Nurex. You have BTK across many different indications, and you also have a partnership with many INI, and then also you have your earlier pipeline.

Arthur T. Sands, CEO

Yes, so Nurex Therapeutics is a phase three oncology and immunology company. We're focused in our advanced program on BTK. We have a novel BTK degrader called Bexabrutideg, or BexDeg for short. It's in development for chronic lymphocytic leukemia. We started the Phase III program this fall. In June, we announced a major partnership with Roche around this program, which is not only CLL-based, but also NHL. And, of course, we'll talk more about potential combinations with Beck-Stegg. In those areas. And we also have a phase two study going for potential accelerated approval in CLL. That's third line plus CLL, so very advanced patients, about 100 patients in that trial. The phase three is about 620 patients targeting that. We also have other drugs in development. We just launched a large phase 1B trial for NX1607, which is our SIBIL inhibitor. It is, we're blocking an E3 ligase there, so rather than degrading proteins, we're blocking the degradation of proteins, which leads to activation of T cells and NK cells, so it's an immuno-oncology agent. We're in, we're outlined a study that we've launched for 120 patients across four indications, Melanoma, lung, colorectal cancer, and prostate. In addition, another cohort in combination with PD-1 therapy, so the major solid tumor program. And then with our partner, Gilead, we have an autoimmune disease program that's finishing phase one. That's a novel IRAC IV degrader, so we look forward to future data from that. In addition, we have a large preclinical pipeline, which I'm sure we can talk more about as we get into detail. So we're based in the Bay Area in San Francisco. Again, been focused on E3 ligase science and how to harness E3 ligases to alter protein levels in the cell.

Roger Song, Analyst — Jefferies

Excellent. Thanks, Arthur. All right, maybe we'll talk about the backstay first for, I think you just announced you will have an MSD event at ASH, and it seems you will give us some updates from your phase one, two, and then also maybe some of the ongoing pivotal trial. So what should we expect from this phase one trial, you know, 1A and 1B for the longer follow-up and then understanding when the other BTK also will have some updates, how we can make a cross-trial comparison with that update.

Arthur T. Sands, CEO

Yeah, so for this ASH, we focused our presentation on the 600 milligram dose groups, plural, so the phase 1A and B groups. Some of our most longest-term treated patients are, of course, in the phase 1A. And what you'll see there, as published in the abstract so far, is the ongoing ORR rate at approximately 85 percent, So reinforcing the 83% we'd previously published. Very consistent results as time goes on. We have a stable PFS at 22.1 months. This is in third to fourth line patient population in CLL, so these are very advanced patients, and so these rates are, I think, really continue to be very encouraging. Also, within that poster, we're going to feature some of the earlier lines of patients. So treatment-naive patients, we have a small cohort there that we'll report on, and also completely treatment-naive, so truly first line, but then also BTK inhibitor-naive patients. So earlier stage, and what we're doing there is really setting the stage for potentially moving up in lines of therapy into the front line ultimately, and we have plans underway for that. So that'll be mainly the ASH update.

Roger Song, Analyst — Jefferies

Excellent. Anything update from the ongoing period of trial? You have multiple period of trial, either ongoing or planned. Any updates from Diane?

Arthur T. Sands, CEO

Well, we really won't have updates from those trials yet. The phase three is a second line CLL program that just started in the fall. So we need to, you know, continue to open sites and gain momentum for enrollment. And then in 2027, we'll have, be able to have some forecasts for enrollment timing. The phase two, the phase, which is the third or fourth line plus patients. We'll be giving an enrollment update in 2027 also on that program.

Roger Song, Analyst — Jefferies

Got it. Okay, good. One abstract from the other competitor, BTK degrader, it's showing some cerebral loss and resistance, you know, didn't happen to their degrader. What's your view on that? And then, you know, is that real in the real world? Or, you know, how are you in your lab? And have you tested different cerebral loss and resistance?

Arthur T. Sands, CEO

Yeah, it's interesting. We're familiar with that abstract. My understanding of it from their work is it's largely an in vitro finding of cereblon loss contributing, because cereblon is a ligase that's being harnessed here to degrade B2K, both for the B1 compound and for us. So we've actually done a very thorough study in patients looking at progressors and sequencing them very thoroughly, and we've never seen cereblon loss in our patients and the progressors. We don't think that's really a real-world finding, as you put it. We have seen other mutations contributing to progression. These patients have really quite a genetic burden of mutations, not just BTK or BTK pathway mutations, but P53, other high-risk mutations, really a collection of them. So it becomes, you know, with advanced patients, genetic burden becomes an issue no matter what. But cereblon loss has not been one of them, so that's kind of interesting.

Roger Song, Analyst — Jefferies

Okay. So based on what you have, those kind of progressors doing this genetic testing or sequencing, what kind of resistant mutation do you think, you know, Backstack is very well suited and then anyone, do you have some trouble to address so far?

Arthur T. Sands, CEO

Yeah. So I'm... Referencing from memory a cancer discovery article, I think, that we published recently in July on this with our colleagues at Memorial Sloan Kettering, who have been actually great investigators for us since early on in the Bexteg program, and they were the ones that identified first some of the pertibrutinib resistance mutations. They were an early trial site for pertubrutinib. So, with regard to the work there, we have found, and others have found, this particular mutation called the A428D mutation, I believe, NBTK, that's the amino acid that's mutated. And that appears to confer what appears to be resistance to not only BTK-degraders, but also all inhibitors. However, it's a very interesting mutation because the clones are not fit clones. They're not physically fit, if you will. They don't grow well. They also block that mutation actually hinders the BTK protein itself. So rather than being a highly active protein, it's actually not a very active protein. So it's not really clear if that's a driver mutation or really a passenger type of mutation with the other mutations that are occurring in the cell. In addition, and I think in that paper, we showed that if you combine a degrader with venetoclax, you actually clean up that mutation and it goes away. So we don't think that that's going to be a clinically significant mutation.

Roger Song, Analyst — Jefferies

Got it. So far, that's the only finding.

Arthur T. Sands, CEO

And that's the only one, and so it fits with our hypothesis that degrading BTK is actually hard to get around. The cell finds it difficult to mutate around, and so you'd have to activate other pathways.

Roger Song, Analyst — Jefferies

Got it. Okay, great. And then you say you're not going to have too much enrollment guidance at this point, but just so far it's on track because, you know, you want to enroll postpartum, But it is still not widely used, and did I have any trouble to enroll those patients post-Purdo in Phase II?

Arthur T. Sands, CEO

Yeah, in the Phase II. So we hope to complete enrollment, and we will complete enrollment, we believe, in 2027. It's just putting a fine point on that, we're not prepared to cite a target date yet. These are post-Purdo patients. Again, it's a target of around 100 patients. These are fairly rare patients to find because, again, it's essentially fourth-line treatment. These are patients that have progressed on a covalent BTK inhibitor, a BCL-2 inhibitor, as well as protobrutinib, the first non-covalent inhibitor. So it's a total, you know, unmet medical need population.

Roger Song, Analyst — Jefferies

And then this is a phase two that potentially can support accelerated approval. So any minimum follow-up is required by the FDA, and then what's any kind of a sharehold on the OR, DOR side that they can support or accelerate their approval?

Arthur T. Sands, CEO

Yeah, so the ORR would be the primary endpoint. And, again, since there's no approved therapy, I mean, I think we believe anything above 50% ORR would be clinically meaningful. Obviously, that's a review issue at the time. The FDA will, you know, make rulings on that. But certainly that historically has been clinically meaningful. And the early patients we've seen in this group, you know, we've seen above a 60 percent or approaching 70 percent ORR rate. So we do see good responses. But these patients are challenging to treat. They are challenging to treat. They've seen a lot of therapies and, again, carry a very large genetic burden. But we do get responses that we think are quite meaningful.

Roger Song, Analyst — Jefferies

Got it. And so would you give us some update at ASH on this triple exposed patient at all? Because you mentioned the earlier line, the naive and the BTK naive patient.

Arthur T. Sands, CEO

So we do have a small number of them within the phase 1A population. But in the earlier line patients, of course, these are treatment-naive and BTK-naive, so no, we won't have a large number of triple-exposed patients.

Roger Song, Analyst — Jefferies

Would you have some updates from them in terms of durability and then the follow-up, or that cohort is not really the focus for them?

Arthur T. Sands, CEO

It's really not the focus, and I think you need to get the numbers up, which is really the purpose of the Phase II program. Otherwise, the numbers are just too small in terms of their representation within the larger group.

Roger Song, Analyst — Jefferies

Got it. And then the phase three confirmatory study is a second line compared to head-to-head compared to a portal. But what's the statistics around that, you know, into the PFS assumption on the heather ratio? And then the recent rate portal, they move into the, you know, they got a label for a first line. Would you have any enrollment issue, you know, when you start to enroll the patient naive to the portal?

Arthur T. Sands, CEO

Yeah, so we've studied the results from protibridinib as a monotherapy that are available to date. And so we built our trial based on certain assumptions regarding their PFS, their reported PFS and ORR. We haven't disclosed what our statistical analysis plan is exactly, but it leads us to believe we can show superiority targeting about 600 patients, 620 patients in that trial. It is a head-to-head, so I think it will be an important study. It does mirror what B1 is doing, so they're also conducting that study. I think they were originally at 500 patients, but they moved it up to 600 recently. So these will be very important studies for the field because they're the first to directly compare head-to-head the degrader mechanism with the inhibitor mechanism. Now, there's many other molecular and cellular reasons to believe the Bexteg will be, will prove out to be superior. If you look at the mutations that are coming up in the second line. Again, these are patients that have all been on a covalent inhibitor. You're starting to see a mutational spectrum that goes beyond the C481S mutation. That was the original mutation of the cysteine that abrogated activity of the covalent BTK inhibitors. But now, with increased use of acalabrutinib and xanabrutinib, we're seeing 528D. We're seeing other T474. We're seeing a number of other mutations coming up, and those, protobrutinib, is not highly effective at, whereas our degrader is. So we're seeing a broader spectrum of mutations in the second line, and I think the degrader will have an advantage in that setting. Also, very interestingly, actually, mutations aside, about 40 percent of our patients have BTK mutations, resistance mutations, But 60% are still wild-type BTK, and yet the inhibitors don't work against them. So that's something that's sometimes overlooked. We think that that indicates the scaffolding function of BTK, that there is a signaling function outside of the kinase activity that cannot be addressed by any inhibitor, basically, and we're seeing that in the clinic. So we think we'll have an advantage even against wild-type BTK.

Roger Song, Analyst — Jefferies

Yeah, that's right. And then in terms of enrollment, do you see because you already started and then they just got approval on the first line data, so how do you think about enrollment for the PIRDO patient?

Arthur T. Sands, CEO

So we are interested in the first line and probably approaching the first line in a combination approach.

Roger Song, Analyst — Jefferies

Oh, and for the monotherapy. Phase III had to have against the PRDOT-brutinia because those patients will be PRDOT-naive patients, right?

Arthur T. Sands, CEO

Oh, yeah, they're required to be PRDOT-naive, yeah.

Roger Song, Analyst — Jefferies

Do you see that the reason that PRDOT first-line approval, will that change the enrollment and how the PRDOT is adopted in the first line?

Arthur T. Sands, CEO

Right. So, yeah, with PRDOT's use in the first line, will it change the spectrum of patients in the second line? We don't think so. It's still early. The adoption of PERDO in the first line I don't think is really going to alter the bulk setting there. The vast majority of patients still receive the covalence in the first line, so we don't anticipate that being an issue.

Roger Song, Analyst — Jefferies

Got it. Okay, yeah, let's talk about the combination. So that probably is appropriate for the earlier line. So when are we going to see more combination data, and then what's the next step for the earlier line?

Arthur T. Sands, CEO

So we have just launched our initial combination trial with. This is Venetoclax, so combining Bexteg with Venetoclax. This is a dose escalation trial, very limited escalation. We're starting that to find the best dose for the combination, and then rapidly, the concept would be to expand. And that would be an all-oral combination. We think that could be attractive in the front line, but we haven't committed to, you know, our front line combination strategy yet. In addition, with Roche, we're looking at several other antibody combinations as well with Bexteg. And since they have, you know, really quite a formulary there to select from, we think that's going to be a big advantage with them. So the combination program is really going to get well underway in 27. The first cohorts running with Venet are running now, so that will be the leading edge. But we won't have data until 27.

Roger Song, Analyst — Jefferies

Okay, data will be 2027. And then with the data, you probably will more articulate on the plan.

Arthur T. Sands, CEO

The overall combo strategy, yeah. It definitely is where the field is going. At least half of the patients, we think, in the front line will ultimately be some combination therapy. So we definitely need to be there to maximize the market opportunity.

Roger Song, Analyst — Jefferies

Got it. Okay. And then the backstack is also you have, you know, with the partnership with Roche, you plan to do two, at least the initial I-9 indication. One is CSU, the other one is MS. So for the CSU, I think you will enter the clinic next year first. And then what's the target profile compared to the inhibitor? Because we have a newly approved, you know, label looks pretty okay and definitely can something and efficacy can be improved. So what's your target profile for the degrader for CSU?

Arthur T. Sands, CEO

So before the Roche deal, we were really looking at primarily CSU and MS. And with Roche, we're considering those, of course, but we're actually broadening our view of the world in terms of what we could look at in terms of INI. So I think that with Roche, we're working diligently to evaluate many different autoimmune indications. And seeing where we think the degrader would be the best, you know, play. So originally, yes, before Roche, we had targeted actually, you know, an I&D this year. But now we're targeting a decision point in 2027 with regard to where we go with INI and Bexteg. There's lots of opportunity, and I think it's important to really pick the best one. There's several things to consider with a dual indication strategy, same molecule, dual branding strategy, dose, the formulation. We did just complete the healthy volunteer study and reported some data there. So there's several things that are at play there to consider which indication ultimately to go for.

Roger Song, Analyst — Jefferies

Got it. Okay, so, you know, are you generating new data to support the decision, which the first or second, the I&I indication, or so when you make the decision, we will see some more data from?

Arthur T. Sands, CEO

Yeah, so the healthy volunteer data with the new formulation was very important, and we did just report some data from that study at a recent meeting in Boston. There, we showed that, and this is actually very important for the field, that we saw no QT prolongation through our QT analysis. That's obviously very important for cardiovascular safety. That had been a bit of a question mark for degraders. People thought, well, is this something, because some have reported QT issues. Is this a degrader issue? And so we see with Becksteg no effect on QT prolongation, so that was important. And then we've also seen, we've done our preliminary drug-drug interaction studies, which were also clean. So it really opens up the field to in multiple indications. But so far, and that will be part of the consideration for what we choose ultimately.

Roger Song, Analyst — Jefferies

Got it. But at this point, it's not necessarily real the CSU and then MS. Or that's the decision will be beyond CSU and MS. So just two, three, you know, just number-wise and then indication-wise.

Arthur T. Sands, CEO

Okay, so could you repeat that?

Roger Song, Analyst — Jefferies

Yeah, just the decision you're going to make is within CSU and MS, or you will go beyond CSU and MS on top of the...

Arthur T. Sands, CEO

Yeah, the consideration will be beyond CSU and MS. So at this point, it's not that you will definitively go to the CSU and MS. Right, that's correct.

Roger Song, Analyst — Jefferies

Got it. All right, good. Recently, you have some surprise from your another partner, Sanofi, and I know we cannot, not having that conversation for the fireside chat. So, any updates from there? Because I know, remember, you talked with them, you know, you have a lot of questions for them. They have not yet answered all the questions. Any updates since...

Arthur T. Sands, CEO

Right. Well, I'm glad you saved the topic for the end. So, yeah, this is with regard to the stat six, termination of the stat six phase one program. Which we just found out about from Sanofi, I think a couple weeks ago. So we have very limited information. This is a program that they had licensed as STAT-6 degrader. They had licensed from us a year and a half ago. Under the agreement, which started in 2019, they have exclusive rights to the STAT-6 program, and then they take over control, and they control the GLP studies as well as the Phase 1, After which, we would have an option to opt back in. So, this was under their control period. We really had no visibility to their decision-making process. We have requested to see all the data. So, so far we have not reviewed any of the data.

Roger Song, Analyst — Jefferies

Okay.

Arthur T. Sands, CEO

And nor received it from them. We would like to see the full reports on both the non-clinical tox package and any clinical information they have. But at this point in time, I really can't provide much information. It is a Sanofi program, and it is an ongoing collaboration. So there are STAT6 backup molecules and additional molecules that are within that collaboration. And there's also an additional target within the collaboration, which was licensed at the same time as the STAT6 program. It's a novel transcription factor. So it's an ongoing collaboration, and we hope to have updates in the near future.

Roger Song, Analyst — Jefferies

Got it. And then just be clear, Sanofi does have their own inhibitor, and then when they terminate this particular program, it's not necessary they terminate the entire STAT-6 program or the partnership with you.

Arthur T. Sands, CEO

Right. So they have not terminated the partnership with us, nor the other STAT6 programs that derive from our partnership with them. And, you know, as you build a whole drug discovery program, there are many molecules moving at any one time, backup molecules, follow-ons. So those are all still part of the alliance.

Roger Song, Analyst — Jefferies

Got it. How far away for those backup compounds into clinical?

Arthur T. Sands, CEO

So, we don't know, to tell you the truth. So, we think that they could be advancing towards the clinic, but we have not seen that data either. So, we're hoping for a whole study update from them.

Roger Song, Analyst — Jefferies

Okay. So, you requested that data as well for the backup?

Arthur T. Sands, CEO

Yes. We'd like to see a whole program update after this event. Got it.

Roger Song, Analyst — Jefferies

Okay. All right. So last 30 seconds. Iraq, that's another partnership. Anything? Because it's also a Gilead program, the same situation. So any updates?

Arthur T. Sands, CEO

Well, hopefully it's not the same situation. Not the same situation.

Roger Song, Analyst — Jefferies

Same partnership in terms of, yeah.

Arthur T. Sands, CEO

Same structure in a way, yeah. So they're completing phase one. Everything we've heard to date has gone well with the program. That's different. There's good communication with Gilead, but they will come up on a governance decision about whether or not to advance to phase two, we think, in the near future. So we'll keep you posted on that.

Roger Song, Analyst — Jefferies

Great. Thanks, Al, sir.

Arthur T. Sands, CEO

Great. Thanks a lot, Roger.

Roger Song, Analyst — Jefferies

Thank you. Thank you, everyone.